A valid prescription requires a telehealth consultation with a licensed provider. No medication is dispensed without clinical evaluation.
Tirzepatide
Dual GLP-1 / GIP Incretin Agonist
Compound Specifications
Tirzepatide
Dual GLP-1 / GIP Incretin Agonist
Tirzepatide is a pioneering dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor co-agonist. In clinical trials, simultaneous activation of both incretin pathways demonstrated significant body weight reduction and improvements in glycemic and metabolic markers.
Simultaneously engages GIP and GLP-1 receptors, enhancing pancreatic beta-cell sensitivity, supporting adipose lipid metabolism, and minimizing nausea often seen with single-pathway agonists.
Documented Therapeutic Benefits
Results may vary. Individual outcomes depend on adherence, baseline health, and other factors.
Administered once weekly subcutaneously, starting at 2.5mg and titrated every 4 weeks under physician direction.
Frequently Asked Clinical Questions
Why is Tirzepatide preferred over single GLP-1s?
The dual GIP/GLP-1 mechanism delivers deeper metabolic activation and greater average weight loss with an exceptional tolerability profile.
Where is Tirzepatide compounded?
All preparations are prepared and dispatched from licensed U.S. compounding pharmacies pursuant to a valid prescription.